#1
|
|||
|
|||
Íåéðîòðàíñïëàíòàöèÿ
Óâàæàåìûå äîêòîðà!  ïîñëåäíåå âðåìÿ âñå ÷àùå è ÷àùå óïîìèíàåòñÿ òåðìèí "ñòâîëîâûå êëåòêè" è ãäå îíè òîëüêî íå ïðèìåíÿþòñÿ... Íåäàâíî óçíàë, ÷òî ñóùåñòâóåò äàæå êîñìåòè÷åñêèå ñðåäñòâà ñîäåðæàùèå ñòâîëîâûå êëåòêè. À ïàöèåíòû? ×óòü ëè íå êàæäûé òðåòèé ñïðàøèâàåò ïðî ëå÷åíèå ñòâîëîâûìè êëåòêàìè. Ìíîãèì ïàöèåíòàì (áîëüøàÿ ÷àñòü èç ðåãèîíîâ Ðîññèè) ïðîâîäèëàñü êëåòî÷íàÿ òåðàïèÿ â âèäå ëþìáàëüíîãî ââåäåíèÿ ñóñïåíçèè êëåòîê. Íî ñàìîå óäèâèòåëüíîå, ÷òî íèêòî íå ïîíèìàåò ïîñëåäñòâèé òàêîãî ëå÷åíèÿ.
Äîêòîðà, åñëè âû çíàåòå î íåãàòèâíûõ ïîñëåäñòâèÿõ ïðèìåíåíèÿ ñòâîëîâûõ êëåòîê - ïèøèòå, îá ýòîì äîëæíû çíàòü âñå!!! |
#2
|
||||
|
||||
Òàê ýòî Âàøè êîëëåãè (èç Ìîñêâû) ýòèì è çàíèìàþòñÿ, ñâÿæèòåñü ñ íèìè è óçíàåòå, íàñêîëüêî ýòè ìåòîäû çàêîííî ïðèìåíÿòü íà ëþäÿõ:
Bull Exp Biol Med. 2001 Mar;131(3):203-12. Neural stem cell: biology and prospects of neurotransplantation. Sukhikh GT, Malaitsev VV. Institute of Biological Medicine, Moscow. Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):149-54. Evaluation of progenitor cell cultures from human embryos for neurotransplantation. Poltavtseva RA, Marey MV, Aleksandrova MA, Revishchin AV, Korochkin LI, Sukhikh GT. Institute of Biological Medicine, Moscow, Russia. Êîå-êòî òàêæå çàíèìàåòñÿ ýòèì è çà ðóáåæîì (òîæå â ýêñïåðèìåíòå): Price J, Uwangho D, Peters S, Galloway D, Mellodew K. Neurotransplantation in neurodegenerative disease: a survey of relevant issues in developmental neurobiology. Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK. Novartis Found Symp. 2000;231:148-57; discussion 157-65. Review. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15256-61. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Bulte JW, Zhang S, van Gelderen P, Herynek V, Jordan EK, Duncan ID, Frank JA. Laboratory of Diagnostic Radiology Research Clinical Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA. |
#4
|
||||
|
||||
Ðå÷ü øëà íå î òðàíñïëàíòàöèè êëåòîê âîîáùå, à î ýòè÷íîñòè ââåäåíèÿ ñòâîëîâûõ êëåòîê ýíäîëþìáàëüíî, ïðè÷åì ïî ïîêàçàíèÿì, íàñêîëüêî ïîíÿë èç Âàøåãî ïîñòèíãà.
À ðàçâå íå êîíêðåòíî íàïèñàë?: Ñóõèõ Ã.Ò. è êîìïàíèÿ èç ñòîëè÷íîãî èíñòèòóòà áèîëîãè÷åñêîé ìåäèöèíû, äóìàþ, èõ êîîðäèíàòû íåñëîæíî íàéòè íà èíñòèòóòñêîì ñàéòå â èíòåðíåòå... |
#5
|
|||
|
|||
Ïðè÷åì çäåñü ýòè÷íîñòü è Ñóõèõ.
Ðå÷ü èäåò î ñâåäåíèÿ, êîòîðûå óòàèâàþòñÿ... î íåãàòèâíûõ ðåàêöèÿõ îðãàíèçìà íà òðàíñïëàíòàöèþ êëåòîê. Êòî î íèõ ñëûøàë, ìîæåò ìíå ñîîáùèòü, ïðè÷åì ìíå èíòåðåñíî ìíåíèå íåçàâèñèìîãî èñòî÷íèêà. |
#6
|
|||
|
|||
Ïðîñòèòå, óâàæàåìûé Stankov!
Ðàç Âû íà ôîðóìå ÍÈÈÒèÈÎ ïðåäñòàâëÿåòå, è òàê íàñòîé÷èâî èíòåðåñóåòåñü «íåãàòèâíûìè ïîñëåäñòâèÿìè», òî ñëåäóåò ïîëàãàòü Âû ÷òî-òî î íèõ çíàåòå? Ìîæåò Âàì è íà÷àòü ðàçãîâîð îá ýòèõ ïîñëåäñòâèÿõ? |
#7
|
|||
|
|||
Òåìà ìîåé äèññåðòàöèè - íåéðîòðàíñïëàíòàöèÿ â ëå÷åíèè òðàâìû ñïèííîãî ìîçãà. Ðàáîòà âûïîëíÿåòñÿ íà ýêñïåðèìåíòàëüíîé áàçå ÃÓ ÍÈÈÒèÈÎ ÌÇ ÐÔ. Ìîÿ ðàáîòà âûïîëíÿåòñÿ íå íà ëþäÿõ, õîòÿ â íàøåé ñòðàíå ìåòîä ïðèæèëñÿ â êëèíèêàõ óæå áîëåå 15 ëåò...
Öåëü ýòîãî ôîðóìà - óçíàòü áîëüøå î ïîáî÷íûõ ýôôåêòàõ è îñëîæíåíèÿõ. ×òî çíàþ îá ýòîì ÿ: 1. Ñàìîå ÷àñòîå îñëîæíåíèå ïðè ââåäåíèè íåéðîíàëüíûõ êëåòîê âûäåëåííûõ èç ýìáðèîíîâ ÷åëîâåêà (àáîðòèâíûé ìàòåðèàë ñðîêîì äî 9 íåäåëü) - ñóáôèáðèëèòåò. 2. Ìîæåò áûòü àíàôèëàêòè÷åñêèé øîê, íî ÿ ñ íèì íå ñòàëêèâàëñÿ. 3. Îòäàëåííûå ïîñëåäñòâèÿ êëåòî÷íîé òåðàïèè. Ëè÷íûõ íàáëþäåíèé ó ìåíÿ ïî ýòîìó âîïðîñó íåò, íî åñòü èññëåäîâàíèÿ çà ðóáåæîì http://link.springer.de/link/service...3/32500282.htm . Êîììåíòàðèé íà ðóññîì çäåñü . Äîêòîðà, óáåäèòåëüíàÿ ïðîñüáà: ïèøèòå åñëè çíàåòå îá ïîñëåäñòâèÿõ êëåòî÷íîé òðàíñïëàíòàöèè, åñëè íå çíàåòå íå ïèøèòå, åñëè õîòèòå óçíàòü ñïðàøèâàéòå! |
|
#8
|
|||
|
|||
ñëó÷àéíî ñàéò íå íà ýòó òåìó [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Âîîáùå-òî ÿ íå âðà÷, à íåðîõèðóðãè÷åñêèé ïàöèåíò (ëèöî òîæå çàèíòåðåñîâàííîå), ïîýòîìó ññûëêà áûëà äàíà ñ âîïðîñîì, à íå â êà÷åñòâå ðàêëàìû. Åñëè íåñïåöèàëèñòó íåïîçâîëèòåëüíî ïðèíèìàòü ó÷àñòèå â äèñêóññèè íàäî îá ýòîì äîïîëíèòåëüíî ñîîáùàòü (â ïðàâèëàõ ôîðóìà ÿ òàêèõ îãðàíè÷åíèé íå íàøëà). |
#9
|
|||
|
|||
Âàøå ññûëêà íà òåìó "Íåâåðîÿòíîå ïóòåøåñòâèå íåçíàéêè íà ëóíó"
Òåìà ôîðóìà - íåãàòèâíûå ïðîÿâëåíèÿ íåéðîòðàíñïëàíòàöèè. Äàâàòü ëèíêè íà ñàéòû, ãäå ãîâîðèòñÿ î ïîëíîé ïîáåäå íàä âñåìè áîëåçíÿìè íå íàäî - îá ýòèõ äàííûõ ÿ çíàþ. ----------------------------------------- P.S. Ïî ñåêðåòó ñêàæó, ÷òî ïðîåêòCellTranspl.ru áóäåò çàêðûò â íîÿáðå 2003 ãîäà... ÍÈÈÒèÈÎ [ ÃÓ ÍÈÈ òðàíñïëàíòîëîãèè è èñêóññòâåííûõ îðãàíîâ ÌÇ ÐÔ] ê íåìó íå èìåëî è íå èìååò íè êàêîãî îòíîøåíèÿ. Îôèöèàëüíûé ñàéò ÍÈÈÒèÈÎ íàõîäèòñÿ çäåñü . |
#10
|
|||
|
|||
Óâàæàåìûé Stankov!
Ñðàçó ïðèçíàþñü, ÷òî ñ êëåòî÷íîé òðàíñïëàíòàöèåé íå ñâÿçàí è çíàêîì ñ íåþ òîëüêî ïî ñòàòüÿì, êîòîðûå âñòðå÷àëèñü. Íî ìíå íå ñîâñåì ïîíÿòíà Âàøà ïîçèöèÿ. Âû ïîëàãàåòå, ÷òî äàííûõ ïî ïîáî÷íûì ïîñëåäñòâèÿì, êîòîðûå Âû ïðèâåëè äîñòàòî÷íî, ÷òîáû ñ ýòèì íàïðàâëåíèåì íå ñïåøèòü? Íî, åñëè õîòÿ áû íàïîëîâèíó ñîîòâåòñòâóþò äåéñòâèòåëüíîñòè âîçìîæíîñòè, êîòîðûå ñâÿçûâàþò ñî ñòâîëîâûìè êëåòêàìè, òî ýòè÷íî ëè «ýòî íå ñïåøèòü» ïî îòíîøåíèþ òåì áîëüíûì, êîòîðûì, òàêèì îáðàçîì, çàêðûâàþòñÿ ïîñëåäíèå íàäåæäû? È ïîòîì, ïî÷åìó àêöåíò òîëüêî íà âîçìîæíûå ïîáî÷íûå ïîñëåäñòâèÿ, áåç ðàññìîòðåíèÿ ïîòåíöèàëüíûõ ëå÷åáíûõ âîçìîæíîñòåé òåðàïèè? Âåäü ðàññìàòðèâàÿ ïîä òàêèì óãëîì, ìîæíî è áîëüøóþ ÷àñòü ïðèâû÷íîé ìåäèêàìåíòîçíîé òåðàïèè ïðèîñòàíîâèòü. |
#11
|
|||
|
|||
Ìíå íå èíòåðåñíî îáñóæäàòü òåìó ýôôåêòèâíîñòè êëåòî÷íîé òåðàïèè íåâðîëîãè÷åñêèõ çàáîëåâàíèé. ß äóìàþ, ÷òî åñëè îòðêðûòü ôîðóì íà ïîäîáíóþ òåìó, òî òàì áóäåò ìíîãî ðàññêàçàíî... ìîæåò áûòü äàæå è ðåàëüíûå ñëó÷àè... ìîæåò áûòü è ÿ áû, ÷òî-íèáóäü ðàññêàçàë...
Íî íàøà ñåãîäíÿøíÿÿ òåìà ñîâåðøåííî äðóãàÿ. Ýôôåêòû ïîáî÷íûå, îñëîæíåíèÿ.... Ñïàñèáî çàðóáåæíîìó äîêòðîðó çà ñëó÷àé èç ïðàêòèêè (ðåàêöèÿ íà ââåäåíèå) è ïîäðîáíîå îïèñàíèå. È âû äîêòîðà, åñëè áîèòåñü çàÿâëÿòü î ñåáå íåãàòèâ íà ôîðóìå ïèøèòå íà e-mail: stankov@celltranspl.ru - ÿ îáÿçàòåëüíî îòâå÷ó, åñëè âàø ñëó÷àé ìíå çíàêîì, òî îáÿçàòåëüíî ðàññêàæó êàê áîðîòüñÿ ñ îñëîæíåíèÿìè. Îáìåí ïîäîáíûì îïûòîì ïðîñòî íåáõîäèì äëÿ óñïåøíîé ðàáîòû. |
#12
|
||||
|
||||
Lancet. 2002 Jun 8;359(9322):2007.
Are dyskinesias a problem after neural transplantation for Parkinson's disease? Bradbury J. Severe dyskinesias are not an inevitable consequence of transplantation for Parkinson's disease, conclude Olle Lindvall (Wallenberg Neuroscience Center, Lund, Sweden) and colleagues in a retrospective analysis of patients given fetal neural transplants. Nevertheless, says Lindvall, "we must discover why dyskinesias sometimes occur so that we can avoid them in future". The first clinical transplantations of fetal neural cells for the treatment of Parkinson's disease were attempted in 1987. Subsequent small open-label studies showed that transplanted cells survive, release dopamine, and become fully integrated into host brains, and that some patients experience neurological improvements. In March, 2001, Curt Freed (University of Colorado School of Medicine, Denver, CO, USA) and colleagues reported the first placebo-controlled study of neural transplantation (N Engl J Med 2001; 344: 710–19). "Transplants improved standardised tests of motor function in patients with advanced Parkinson's disease", says Freed. "However, 15% of our patients developed excessive abnormal movements similar to those they had had while taking L-dopa." "This result was written about a lot", comments Lindvall. "Because it was proposed that the dyskinesias were due to a dopamine excess produced by an overgrowth of grafted tissue, it raised fears that it would be impossible to develop cell therapy for Parkinson's disease." To investigate this, Lindvall and colleagues re-evaluated 14 patients given neural transplants during the past 11 years (Nat Neurosci; published online 3 June 2002; DOI: 10.1038/nn863). "Overall, there was an increase in mild-to-moderate dyskinesia", says Lindvall, "but dyskinesia severe enough to be a clinical problem occurred in only one patient. Importantly, we found no correlation between the occurrence of the worst dyskinesias and graft growth or clinical improvement." Lindvall proposes two explanations for dyskinesia after transplantation. "It could be caused by cells other than dopaminergic neurons in the fetal transplant––in the future, transplantation of dopaminergic neurons generated from stem cells could avoid this possibility. Alternatively, it could be that small grafts and areas of hypersensitive dopamine receptors within the host brain result in unstable dopamine signalling." Freed favours Lindvall's suggestion that the dyskinesias reflect an abnormal host brain response to dopamine, but he is not convinced that Lindvall and colleagues can draw the conclusions they do from their analysis. "They describe a group of patients who had transplants with a variety of techniques at different times", he comments. Freed and Lindvall, however, agree that development of neural cell transplantation requires additional prospective, controlled trials. One such trial should be published this year by Thomas Freeman (University of South Florida, Tampa, FL, USA) and co-workers. Noting that Lindvall's study is very interesting, Freeman says that "in our trial, autopsy studies, combined with clinical and PET [positron emission tomography] data, will give a rich dataset to characterise the issues contributing to dyskinesia development after transplantation". |
#13
|
|||
|
|||
Áîëüøîå ñïàñèáî çà îòâåò!!!
ß ñëûøàë ïðî èññëåäîâàíèÿ Lindvall, ÿ òàêæå çíàþ, ÷òî ó íåãî áûë ñëó÷àé, êîãäà ïàöèåòó ââåëè ìå÷åíûå êëåòêè è îí ïîãèá â àâòîêàòàñòðîôå è èõ íàøëè â òêàíè ìîçãà. À ââîäèëè èõ ëþìáàëüíî. Òåì ñàìûì áûëî ïîêàçàíî, ÷òî êëåòêè ïîñëå òðàíñïëàíòàöèè äðåéôóþò â æåëóäî÷êîâîé ñèñòåìå, ïðèêðåïëÿþòñÿ ê ýïåíäèìå æåëóäî÷êîâ, âíåäðÿþòñÿ â òêàíü ìîçãà è ïåðåìåùàþòñÿ ê ìåñòó òðàâìû ïî òðàíñïîðòíîé ãëèè. |
#14
|
|||
|
|||
Óâàæàåìûé äîêòîð Stankov!
ß çàíèìàëñÿ íåêîòîðîå âðåìÿ íåéðîòðàíñïëàíòàöèåé íà æèâîòíûõ. Êëåòêè ó÷àñòêà ìîçãà ðàçðóøàëèñü ôàðìàêîëîãè÷åñêèì ïóòåì. Çàòåì ââîäèëèñü ñòâîëîâûå êëåòêè. Ñåé÷àñ ýòà ðàáîòà òîæå ïðîäâèãàåòñÿ, íî óæå áåç ìîåãî íåïîñðåäñòâåííîãî ó÷àñòèÿ. Ìíå íå óäàëîñü ïîëó÷èòü äîêàçàòåëüñòâ, ÷òî ñòâîëîâûå êëåòêè ïðåâðàùàþòñÿ â ôóíêöèîíàëüíî ñïîñîáíûå íåéðîíû. Êðèòåðèåì áûëî òî, ÷òî ó æèâîòíîãî íåëüçÿ áûëî âûðàáîòàòü îïðåäåëåííûé óñëîâíûé ðåôëåêñ, õîòÿ íîðìàëüíûå æèâîòíûå åãî âûðàáàòûâàëè áåç òðóäà. Åñòü ëè ó Âàñ ëè÷íî äîêàçàòåëüñòâà òîãî, ÷òî ââåäåíèå ñòâîëîâûõ êëåòîê ôóíêöèîíàëüíî ïåðñïåêòèâíî? |
#15
|
|||
|
|||
Äîêàçàòåëüñòâà
Äà åñòü. Äàííûå ïîêà íå îïóáëèêîâàíû, ïîýòîìó ðàññêàæó êðàòêî. Æèâîòíîå (êîøêà) ñ îïóõîëüþ ãîëîâíîãî ìîçãà óæå ñ òðóäîì ïåðåäâèãàëîñü. Åìó ââîäèëèñü íåéðîíàëüíûå êëåòêè âûäåëåííûå èç êîøà÷üèõ ýìáðèîíîâ â òå÷åíèå ãîäà. Êàê ïðàâèëî íà ñëåäóþùèé äåíü ïîñëå ââåäåíèÿ íàáëþäàëñÿ çíà÷èòåëüíîå óëó÷øåíèå ñîñòîÿíèÿ.
 ýòîé ðàáîòå ñòâîëîâûå êëåòêè íå ïðèìåíÿëèñü. À ÷òî âû ïîäðàçóìåâàåòå ïîä ôóíêöèîíàëüíîé ïîëíîöåííîñòüþ íåéðîíîâ ïîëó÷åííûõ èç ñòâîëîâûõ êëåòîê? ß ñ÷èòàþ, ÷òî åñëè â êóëüòóðå êëåòêè âûáðàñûâàþò àêñîíû è îáðàçîâûâàþò ñèíàïñû, à ïîòîì îêðàøûâàþòñÿ íà ñïåöèôèöåñêèå ìàðêåðû (NSE, GFAP, MAP2), òî ýòîãî âïîëíå äîñòàòî÷íî. Ìîæíî, êîíå÷íî, äîïîëíèòåëüíî åùå ïðîâåñòè èññëåäîâàíèÿ íà ñïîñîáíîñòü íåéðîíîâ ê ïðîâåäåíèþ íåðâíîãî èìïóëüñà... Ìíå èíòåðåñíî, ÷òî âû ìîäåëèðîâàëè â âàøåì ýêñïåðèìåíòå? Êàêèå êëåòêè èñïîëüçîâàëè è ãäå âû èõ áðàëè? |